Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so-familiar routine of meetings, deadlines, and what-not has returned. You knew this would happen, yes? But no need to fret. We have assembled a menu of tidbits to help you along and invite you to join us for a cup of stimulation — vanilla macadamia nut, in our case — to cope. So dig in and have a great day. …
Teva Pharmaceuticals (TEVA) hired Lundbeck’s (LUN) Kare Schultz as its new chief executive, ending a seven-month search for a new leader to jumpstart sales, lower debt, and restore investor confidence after a controversial acquisition spree. Schultz, 56, who has been running Lundbeck and will move to Israel, faces pressure to either to maintain Teva as both a generics and specialty drug maker, split the company in two, or exit generics altogether.
About the Author Reprints
